艾迪康 (ADICON) offers Clinical-trial central laboratory, molecular pathology and biomarkers. Services should be matched to the intended study and assay requirements.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY IFRS / consolidated
2,638,450,000
18,443,000 Net income attributable to owners of the parent
Consolidated group figures include proprietary products and other businesses and are not equivalent to the CRO/CDMO segment.
Uses net income attributable to owners of the parent, rather than group net income including noncontrolling interests. The parent-attributable year-over-year change is not explicitly disclosed and is left blank.
Adjusted earnings were not fully verified in this review and are left blank.
2026H1 · Reporting notes
Consolidated group figures include proprietary products and other businesses and are not equivalent to the CRO/CDMO segment.
Uses net income attributable to owners of the parent, rather than group net income including noncontrolling interests. The parent-attributable year-over-year change is not explicitly disclosed and is left blank.
Adjusted earnings were not fully verified in this review and are left blank.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Clinical-trial central laboratory, molecular pathology and biomarkers
Specialist contract research/testing services
The 2025 annual report reports 31.5% CRO growth and the 2026 interim disclosure reports 34.9% growth; these rates do not represent total group revenue.
Listed entity HKEX 9860; financials are consolidated group figures.
Program / service
Target / indication
Representative stage
Evidence & scope
Clinical research central laboratory / CRO services
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
The group does not separately disclose all CRO/CDMO profit on a directly comparable basis; group valuation or profit should not directly determine assessments of this business.
